EMAIL THIS PAGE TO A FRIEND

Oncotarget

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.


PMID 26415225

Abstract

Inhibition of BET bromodomains (BRDs) has emerged as a promising cancer therapeutic strategy. Accordingly, inhibitors of BRDs such as JQ1 have been actively developed and some have reached clinical testing. However, the mechanisms by which this group of inhibitors exerts their anticancer activity, including induction of apoptosis, have not been fully elucidated. This report reveals a previously uncovered activity of JQ1 in inducing c-FLIP degradation and enhancing TRAIL-induced apoptosis. JQ1 potently decreased c-FLIP (both long and short forms) levels in multiple cancer cell lines without apparently increasing the expression of DR5 and DR4. Consequently, JQ1, when combined with TRAIL, synergistically induced apoptosis; this enhanced apoptosis-inducing activity could be abolished by enforced expression of ectopic FLIPL or FLIPS. Hence it appears that JQ1 decreases c-FLIP levels, resulting in enhancement of TRAIL-induced apoptosis. Inhibition of proteasome with MG132 prevented JQ1-induced c-FLIP reduction. Moreover, JQ1 decreased c-FLIP stability. Therefore, JQ1 apparently decreases c-FLIP levels through facilitating its proteasomal degradation. Genetic inhibition of either BRD4 or c-Myc by knocking down their expression failed to mimic JQ1 in decreasing c-FLIP and enhancing TRAIL-induced apoptosis, suggesting that JQ1 induces c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 or c-Myc inhibition. In summary, our findings in this study highlights a novel biological function of JQ1 in modulating apoptosis and warrant further study of the potential treatment of cancer with the JQ1 and TRAIL combination.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1406737
Anti-CFLAR antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV00022
Anti-CFLAR antibody produced in rabbit, IgG fraction of antiserum
SAB2100411
Anti-CFLAR antibody produced in rabbit, affinity isolated antibody, lyophilized powder
HPA019044
Anti-CFLAR antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
SAB3500428
Anti-DR4 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
D3938
Anti-DR5 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500427
Anti-DR5 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500429
Anti-FLIP antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
AV02065
Anti-TNFRSF10A antibody produced in rabbit, IgG fraction of antiserum
HPA054475
Anti-TNFRSF10A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406725
Anti-TNFRSF10B antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA023625
Anti-TNFRSF10B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2102489
Anti-TNFRSF10B antibody produced in rabbit, affinity isolated antibody
SAB4700538 Monoclonal Anti-CD262 antibody produced in mouse, clone DR5-01-1, purified immunoglobulin, buffered aqueous solution
WH0008837M1
Monoclonal Anti-CFLAR antibody produced in mouse, clone 2F12, purified immunoglobulin, buffered aqueous solution
SAB1404634
Monoclonal Anti-CFLAR antibody produced in mouse, clone 1G1, purified immunoglobulin, buffered aqueous solution
WH0008797M1
Monoclonal Anti-TNFRSF10A antibody produced in mouse, clone 2E8, purified immunoglobulin, buffered aqueous solution
SAB1404626
Monoclonal Anti-TNFRSF10A antibody produced in mouse, clone 2E9, purified immunoglobulin, buffered aqueous solution
WH0008795M1
Monoclonal Anti-TNFRSF10B antibody produced in mouse, clone 2D6, purified immunoglobulin, buffered aqueous solution
SML0352
PFI-1, ≥98% (HPLC)
C16H17N3O4S
T5694 TRAIL human, recombinant, expressed in NSO cells, >97% (SDS-PAGE), lyophilized powder
T9701 TRAIL human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE and HPLC), lyophilized powder